Gland Pharma Ltd

General

Total Cases32

Active Cases6

Patents--

CourtsD. New Jersey D. Delaware E.D. Michigan

TypeOperating Company

Elite Ratings

--

glandpharma.com

Ratings

Experience

Grade

Trend

DCT

L2

E

PTAB

--

--

--

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
09/13/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	BRIEF in Support filed by LA JOLLA PHARMA, LLC, LA JOLLA PHARMACEUTICAL COMPANY, THE GEORGE WASHINGTON UNIVERSITY re [217] MOTION for Partial Summary Judgment (Attachments: # [1] Statement of Undisputed Material Facts Pursuant to Local Rule 56.1, # [2] Exhibit C, # [3] Exhibit D, # [4] Exhibit E, # [5] Exhibit F, # [6] Exhibit G, # [7] Exhibit H, # [8] Exhibit I, # [9] Exhibit J, # [10] Exhibit K, # [11] Exhibit L, # [12] Exhibit M, # [13] Exhibit N)(CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 09/13/2024) BRIEF in Support filed by LA JOLLA PHARMA, LLC, LA JOLLA PHARMACEUTICAL COMPANY, THE GEORGE WASHINGTON UNIVERSITY re [217] MOTION for Partial Summary Judgment (Attachments: # [1] Statement of Undisputed Material Facts Pursuant to Local Rule 56.1, # [2] Exhibit C, # [3] Exhibit D, # [4] Exhibit E, # [5] Exhibit F, # [6] Exhibit G, # [7] Exhibit H, # [8] Exhibit I, # [9] Exhibit J, # [10] Exhibit K, # [11] Exhibit L, # [12] Exhibit M, # [13] Exhibit N)(CHEVALIER, CHARLES)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 09/13/2024)
09/13/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	MOTION for Partial Summary Judgment by LA JOLLA PHARMA, LLC, LA JOLLA PHARMACEUTICAL COMPANY, THE GEORGE WASHINGTON UNIVERSITY. (Attachments: # [1] Declaration of Charles H. Chevalier, # [2] Exhibit A, # [3] Exhibit B, # [4] Text of Proposed Order, # [5] Certificate of Service)(CHEVALIER, CHARLES) (Entered: 09/13/2024)
09/13/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024) CLAIM Construction Chart by MOMENTA PHARMACEUTICALS, INC.. (Attachments: # [1] Appendix Plaintiff's Table of Contents, # [2] Appendix Plaintiff's Ex. B, # [3] Appendix Plaintiff's Ex. C, # [4] Appendix Plaintiff's Ex. D, # [5] Appendix Plaintiff's Ex. E, # [6] Appendix Plaintiff's Ex. F, # [7] Appendix Plaintiff's Ex. G, # [8] Appendix Plaintiff's Ex. H, # [9] Appendix Plaintiff's Ex. I, # [10] Appendix Plaintiff's Ex. J, # [11] Appendix Plaintiff's Ex. K, # [12] Appendix Plaintiff's Ex. L, # [13] Appendix Defendant's Cover Page, # [14] Appendix Defendant's Ex. 1, # [15] Appendix Defendant's Ex. 2, # [16] Appendix Defendant's Ex. 3, # [17] Appendix Defendant's Ex. 4, # [18] Appendix Defendant's Ex. 5, # [19] Appendix Defendant's Ex. 6, # [20] Appendix Defendant's Ex. 7, # [21] Appendix Defendant's Ex. 8, # [22] Appendix Defendant's Ex. 9, # [23] Appendix Defendant's Ex. 10, # [24] Appendix Defendant's Ex. 11, # [25] Appendix Defendant's Ex. 12, # [26] Appendix Defendant's Ex. 13, # [27] Appendix Defendant's Ex. 14, # [28] Appendix Defendant's Ex. 15, # [29] Appendix Defendant's Ex. 16, # [30] Appendix Defendant's Ex. 17, # [31] Appendix Defendant's Ex. 18, # [32] Appendix Defendant's Ex. 19, # [33] Appendix Defendant's Ex. 20, # [34] Appendix Defendant's Ex. 21, # [35] Appendix Defendant's Ex. 22, # [36] Appendix Defendant's Ex. 23a, # [37] Appendix Defendant's Ex. 23b, # [38] Appendix Defendant's Ex. 24, # [39] Appendix Defendant's Ex. 25, # [40] Appendix Defendant's Ex. 26, # [41] Appendix Defendant's Ex. 27, # [42] Appendix Defendant's Ex. 28, # [43] Appendix Defendant's Ex. 29, # [44] Appendix Defendant's Ex. 30, # [45] Appendix Defendant's Ex. 31, # [46] Appendix Defendant's Ex. 32, # [47] Appendix Defendant's Ex. 33, # [48] Appendix Defendant's Ex. 34, # [49] Appendix Defendant's Ex. 35, # [50] Appendix Defendant's Ex. 36, # [51] Appendix Defendant's Ex. 37) (Flynn, Edward) (Entered: 09/13/2024)
09/12/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	ORDER granting [138] view138 Joint MOTION to Extend Time to to file their Joint Disputed Claim Terms Chart and Prehearing Statement. The parties may file their Joint Disputed Claim Terms Chart and PrehearingStatement by September 13, 2024. Signed by Judge Robert J. Colville on 9/12/24. Text-only entry; no PDF document will issue. This text-only entry constitutes the Order of the Court or Notice on the matter. (cjo) (Entered: 09/12/2024) ORDER granting [138] view138 Joint MOTION to Extend Time to to file their Joint Disputed Claim Terms Chart and Prehearing Statement. The parties may file their Joint Disputed Claim Terms Chart and PrehearingStatement by September 13, 2024. Signed by Judge Robert J. Colville on 9/12/24. Text-only entry; no PDF document will issue. This text-only entry constitutes the Order of the Court or Notice on the matter. (cjo) (Entered: 09/12/2024)
09/11/24	Momenta Pharmaceuticals Inc v. Mylan Pharmaceuticals Inc 2:22-CV-00750 ( W.D. PA )	Joint MOTION to Extend Time to to file their Joint Disputed Claim Terms Chart and Prehearing Statement by GLAND PHARMA, LTD., MYLAN PHARMACEUTICALS, INC., MYLAN TEORANTA, MYLAN, INC., NATCO PHARMA, LTD., VIATRIS, INC.. (Attachments: # 1 Proposed Order Proposed Order) (Pietragallo, William) (Entered: 09/11/2024)
09/09/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	LETTER ORDER granting [215] Defendants request unsealing document re [211] . Signed by Magistrate Judge James B. Clark on 9/9/2024. (jd, ) Modified on 9/9/2024 (jd, ). (Entered: 09/09/2024)
09/09/24	Bausch & Lomb Inc v. Gland Pharma Ltd 3:22-CV-04345 ( D. NJ )	Pro Hac Vice counsel, Rebecca Lynne Neubauer, has been added to receive Notices of Electronic Filing. Pursuant to L.Civ.R. 101.1, only local counsel are entitled to sign and file papers, enter appearances and receive payments on judgments, decrees or orders. (jal, ) (Entered: 09/09/2024)
09/06/24	La Jolla Pharmaceutical Co v. Gland Pharma Ltd 2:22-CV-01754 ( D. NJ )	Letter from Defendants re unsealing re [211] Letter,,. (RICHTER, JAMES) (Entered: 09/06/2024)
09/06/24	Bausch & Lomb Inc v. Gland Pharma Ltd 3:22-CV-04345 ( D. NJ )	LETTER ORDER granting extension of scheduling deadlines. Signed by Magistrate Judge Rukhsanah L. Singh on 9/6/2024. (jal, ) (Entered: 09/06/2024)
09/06/24	Bausch & Lomb Inc v. Gland Pharma Ltd 3:22-CV-04345 ( D. NJ )	Notice of Request by Pro Hac Vice Rebecca Lynne Neubauer to receive Notices of Electronic Filings. ( Pro Hac Vice fee $ 250 receipt number ANJDC-15643936.) (SENDER, STUART) (Entered: 09/06/2024)